Metformin in Patients With Ulcerative Colitis Treated With Mesalamine

Last updated: April 5, 2025
Sponsor: Tanta University
Overall Status: Completed

Phase

2

Condition

Crohn's Disease

Inflammatory Bowel Disease

Gastrointestinal Diseases And Disorders

Treatment

Metformin

Clinical Study ID

NCT05553704
3422
  • Ages 18-75
  • All Genders

Study Summary

Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa, however, the exact underlying mechanisms of UC remain poorly understood.UC is strongly dependent on cellular immune reaction and exaggerated inflammatory response due to genetic, immune and environmental factors.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years

  • Both males and females will be included

  • Negative pregnancy test and effective contraception

Exclusion

Exclusion Criteria:

  • •

  • Breast feeding

  • Significant liver and kidney function abnormalities

  • Diabetic patients

  • Colorectal cancer patients

  • Patients with severe UC

  • Patients taking rectal or systemic steroids

  • Patients taking immunosuppressives or biological therapies

  • Addiction to alcohol and / or drugs

  • Known allergy to the studied medications

Study Design

Total Participants: 60
Treatment Group(s): 1
Primary Treatment: Metformin
Phase: 2
Study Start date:
November 01, 2022
Estimated Completion Date:
March 01, 2025

Connect with a study center

  • Faculty of Medicine, Mansoura University

    Mansoura, 35511
    Egypt

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.